Patents by Inventor George L. Sing
George L. Sing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220030851Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: October 5, 2021Publication date: February 3, 2022Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Patent number: 10286015Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: April 25, 2017Date of Patent: May 14, 2019Assignee: Noveome Biotherapeutics, Inc.Inventors: George L Sing, Vivienne S Marshall
-
Publication number: 20180288998Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: May 26, 2018Publication date: October 11, 2018Applicant: Noveome Biotherapeutics, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20170224740Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: ApplicationFiled: April 25, 2017Publication date: August 10, 2017Applicant: Noveome Biotherapeutics, Inc.Inventors: George L Sing, Vivienne S. Marshall
-
Publication number: 20170209498Abstract: The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions Amnion-derived Cellular Cytokine Solution (ACCS), including novel immediate-release, targeted-release, and sustained-release (SR) ACCS compositions (referred to herein as “SR-ACCS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions. Such administration includes intranasal administration of ACCS and/or AMP cells.Type: ApplicationFiled: April 6, 2017Publication date: July 27, 2017Applicant: Noveome Biotherapeutics, Inc,Inventors: Larry R. Brown, George L. Sing, Howard C. Wessel
-
Patent number: 9662417Abstract: The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as CFS compositions), such CFS compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ECS cells), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) obtained from culturing Amnion-derived Multipotent Progenitor (AMP) cells, dispersed in a polymeric coating material.Type: GrantFiled: December 16, 2015Date of Patent: May 30, 2017Assignee: STEMNION, INC.Inventors: Larry R Brown, George L Sing
-
Patent number: 9636364Abstract: The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions Amnion-derived Cellular Cytokine Solution (ACCS), including immediate-release, targeted-release, and sustained-release (SR) ACCS compositions (referred to herein as “SR-ACCS” compositions) and/or Amnion-derived Multipotent Progenitor (AMP) cell compositions. Such administration includes intranasal administration of ACCS and/or AMP cells.Type: GrantFiled: December 1, 2014Date of Patent: May 2, 2017Assignee: STEMNION, INC.Inventors: Larry R Brown, George L Sing, Howard C Wessel
-
Patent number: 9623089Abstract: The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS).Type: GrantFiled: October 28, 2014Date of Patent: April 18, 2017Assignee: STEMNION, INC.Inventors: George L Sing, David L Steed
-
Publication number: 20160367602Abstract: The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: September 1, 2016Publication date: December 22, 2016Applicant: Noveome Biotherapeutics, Inc.Inventors: George L. Sing, Randall G. Rupp, David L. Steed
-
Publication number: 20160324928Abstract: The invention is directed to methods for treating blepharitis. The invention is further directed to reducing inflammation associated with blepharitis. The invention is further directed to methods for treating blepharitis and/or reducing inflammation associated with blepharitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: July 5, 2016Publication date: November 10, 2016Applicant: Noveome Biotherapeutics, Inc.Inventor: George L. Sing
-
Publication number: 20160220615Abstract: The invention is directed to methods for treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to treating disorders, diseases and injuries of the cornea and ocular surface. Such methods utilize novel compositions including, but not limited to, trophic factor secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.Type: ApplicationFiled: April 11, 2016Publication date: August 4, 2016Applicant: Noveome Biotherapeutics, Inc.Inventor: George L Sing
-
Publication number: 20160220617Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.Type: ApplicationFiled: April 11, 2016Publication date: August 4, 2016Applicant: Noveome Biotherapeutics, Inc.Inventors: Donna M. Olejniczak, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20160114008Abstract: The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS).Type: ApplicationFiled: October 28, 2014Publication date: April 28, 2016Inventors: George L. Sing, David L. Steed
-
Publication number: 20160106887Abstract: The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as CFS compositions), such CFS compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ECS cells), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) obtained from culturing Amnion-derived Multipotent Progenitor (AMP) cells, dispersed in a polymeric coating material.Type: ApplicationFiled: December 16, 2015Publication date: April 21, 2016Applicant: Stemnion, Inc.Inventors: Larry R. Brown, George L. Sing
-
Patent number: 9314487Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.Type: GrantFiled: May 13, 2014Date of Patent: April 19, 2016Assignee: STEMNION, INC.Inventors: Donna M Olejniczak, David L Steed, Randall G Rupp, George L Sing
-
Publication number: 20160081329Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: December 2, 2015Publication date: March 24, 2016Applicant: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20160015785Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: September 16, 2015Publication date: January 21, 2016Applicant: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20160000874Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: September 16, 2015Publication date: January 7, 2016Applicant: STEMNION, INC.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Patent number: 9220817Abstract: The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as CFS compositions), such CFS compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ECS cells), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) obtained from culturing Amnion-derived Multipotent Progenitor (AMP) cells, dispersed in a polymeric coating material.Type: GrantFiled: March 11, 2014Date of Patent: December 29, 2015Assignee: STEMNION, INC.Inventors: Larry R Brown, George L Sing
-
Patent number: 9173927Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: August 1, 2014Date of Patent: November 3, 2015Assignee: STEMNION, INC.Inventors: Charlotte A Emig, Catherine J Trumpower, George L Sing